Methocarbamol Injection

Methocarbamol is a carbamate derivative of guaifenesin glycerol ether, a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant effects. The exact mechanism of action of methocarbamol in humans is not yet clear, but it may be related to widespread CNS depression. Methocarbamol has no direct effect on the contractile mechanism of skeletal muscle, motor end plates, or nerve fibers.

The main ingredient of this product is methocarbamol. Its chemical name is: (±)-3-[o-methoxyphenoxy]=1,2-propylene glycol-1-carbamate. Its chemical structural formula is: Molecular formula: C11H15NO5 Molecular weight: 241.24 The excipients of this product are polyethylene glycol 300 and water for injection.

This product is a colorless or almost colorless, slightly viscous, clear liquid.

Mainly used for adjuvant treatment of acute skeletal muscle pain or discomfort symptoms.

Intravenous push injection: The patient should be in a lying position and the injection should be slowly pushed. The speed of administration should not exceed 3ml per minute. The patient should rest for at least 10-15 minutes after the injection. Intravenous drip: It should be mixed with 0.9% sodium chloride injection or 5% glucose injection for intravenous drip. The drip rate should not be too fast. The dilution volume of 1.0g should not exceed 250ml. The diluted mixture should not be refrigerated. The dosage and frequency of use are determined according to the condition and treatment effect. The adult dose is 1.0g per time, the maximum daily dose is 3.0g, and continuous use should not exceed 3 days. Mild cases should be changed to oral administration after intravenous injection to maintain treatment. In severe cases or after surgery when oral administration is not suitable, the drug is administered once every 8 hours, reaching the maximum daily dose of 3g, and continuous use should not exceed 3 days. If the condition persists, a course of treatment can be repeated 48 hours after stopping the drug.

Major adverse reactions: allergic reaction, fever, headache. Cardiovascular system: bradycardia, facial flushing, hypotension, syncope, thrombophlebitis. Most cases of syncope can recover naturally. In addition, adrenaline, injectable steroid hormones and or antihistamines can promote recovery. Digestive system: indigestion, jaundice (including biliary jaundice), nausea, vomiting. Blood and lymphatic system: leukopenia. Nervous system: amnesia, confusion, diplopia, dizziness, drowsiness, insomnia, ataxia, nystagmus (including grand mal seizures), vertigo. Skin and special senses: blurred vision, nasal congestion, metallic taste, itching, rash, urticaria. Others: pain, peeling at the injection site.

1. This product uses polyethylene glycol 300 as a solvent, which can aggravate the original acidosis and urea accumulation of patients with renal insufficiency, so it is contraindicated for patients with liver and kidney dysfunction. 2. Pregnant and lactating women are contraindicated. 3. People who are allergic to this product are contraindicated.

Precautions for children: The safety and effectiveness of this product in treating pediatric patients are not yet clear. The empirical dose and management can be used specifically for pediatric tetanus patients. Precautions for pregnancy and lactation: Pregnant and lactating women are prohibited. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference literature.

It should not be used in combination with general anesthetics, hypnotics, tranquilizers and drugs containing ethanol.

Keep in a sealed container

10 ml: 1 g

24 months

Suzhou Pharmaceutical Factory

• Founded in:

  2006-02-14

• Address:

  No. 2-1, Dongwu South Road, Wuzhong District, Suzhou City

• Tax NO.:

  91320506138170408U

• Registered Funds:

  -

• Website:

  Log in to view

• Email:

  Log in to view